Pasithea Therapeutics Corp. (KTTA) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) disorders and RASopathies. The company's primary asset is PAS-004, a next-generation MEK inhibitor currently in a Phase 1 clinical trial for advanced tumors and neurofibromatosis type 1 (NF1). The company discontinued its "Clinics" segment (anti-depression support services) in late 2023, which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(3,866,249) | $(7,727,089) | $(7,300,909) |
| Loss Per Share (Diluted) | $(3.71) | $(7.41) | $(5.59) |
| Operating Expenses | $3,945,034 | $7,985,808 | $7,041,253 |
| Cash & Equivalents (End of Period) | $7,967,569 | $7,967,569 | $26,647,633 |
| Working Capital | $7,247,613 | $7,247,613 | $14,058,114 |
| Cash Used in Operations (YTD) | N/A | $(8,359,951) | $(6,281,944) |
Note: The company has no revenue. Expenses are driven by Research & Development (R&D) and General & Administrative (G&A) costs.
Material Changes vs. Prior Period
- Increased R&D Spend: R&D expenses increased by 31.5% year-over-year (YTD) to $4.1 million. This was primarily driven by a $1.5 million increase in clinical trial costs associated with the initiation of the Phase 1 trial for PAS-004.
- Stable G&A: G&A expenses decreased slightly by 1.0% YTD to $3.9 million, attributed to lower personnel costs and accounting fees, partially offset by higher legal and office expenses.
- Cash Burn: Cash and cash equivalents decreased by approximately $8.4 million during the first six months of 2024, compared to a $6.4 million decrease in the same period in 2023. This reflects the increased operational burn rate.
- Discontinued Operations: Unlike the prior year, there were no losses from discontinued operations in 2024, as the Clinics segment was fully divested in 2023.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management explicitly states there is substantial doubt about the company's ability to continue as a going concern for twelve months from the filing date without additional funding. With approximately $8.0 million in cash, the company estimates it will not have sufficient working capital to meet needs through the next 12 months.
- Capital Needs: The company is dependent on obtaining additional working capital through the sale of equity or debt securities to continue its development plans.
- Clinical Progress: The Phase 1 trial for PAS-004 is ongoing in the U.S., with plans to open additional sites in Eastern Europe in Q3 2024.
- Internal Controls: The company disclosed a material weakness in internal controls related to the review of the annual income tax provision. Management has initiated a remediation plan involving a tax professional.
- Reverse Stock Split: A 1-for-20 reverse stock split became effective on January 2, 2024. All share data in this report reflects this split.
Investor Verification Checklist
- Funding Runway: Verify the timeline for the next capital raise given the explicit "substantial doubt" regarding the 12-month going concern status.
- Phase 1 Trial Status: Monitor enrollment and safety data for the PAS-004 Phase 1 trial, which is the primary driver of current R&D spend.
- Warrant Liability: Review the fair value adjustments of public and representative warrants, which impact net loss but are non-cash items.
- Internal Control Remediation: Confirm the status of the remediation plan for the material weakness in tax provision controls.
- Share Count: Note the impact of the 1-for-20 reverse stock split on share count and per-share metrics when comparing to pre-2024 data.